UBS Group’s BioTelemetry, Inc. BEAT Stock Holding History

UBS Group’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-100	Closed	-$1K	–	10146
2014 Q4	$1K	Buy	+100	New	+$858	﹤0.01%	9634

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

UBS Group's BEAT Position: Q1 2021 in Review

UBS Group sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 55,201 shares — an estimated $3.98M sold.

UBS Group first reported a position in BEAT in Q4 2014 and held it in 25 quarters. The position peaked at $6.03M in Q4 2019. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

UBS Group reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
UBS Group sold 55,201 BioTelemetry, Inc. shares in Q1 2021, an estimated $3.98M.
UBS Group first reported a position in BioTelemetry, Inc. in Q4 2014 and held it in 25 quarters.
UBS Group's BioTelemetry, Inc. position peaked at $6.03M in Q4 2019.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.